| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
RxElite (Main) is a Meridian, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
COVID Tests, Rapid Test, Protocols, Atmofizer, Air Purification, Antigen Test, Antibody Test, My Protect Kit, Coronavirus Detection, David Lee Jensen, Tampa FL
Taylst is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
J M Smith Corporation is a Spartanburg, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.